News

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...
Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...
We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...
Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...
Clever Culture’s APAS is now on trial with Novo Nordisk, and if it delivers, this one machine could unlock a global pharma ...
A US doctor has explained the reality behind the 'Ozempic penis' side effect men have reported having after taking the GLP-1 drug ...
Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...
Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...
Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A ...
Danish pharmaceutical giant Novo Nordisk is set to lose Canadian patent protection on its popular semaglutide-based drugs, ...